Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON43030
NL-OMON43030
Not yet recruiting
Phase 3

Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES) - Post-HERCULES

Ablynx NV0 sites8 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsThrombotic Thrombocytopenic Purpura10038158

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Thrombotic Thrombocytopenic Purpura
Sponsor
Ablynx NV
Enrollment
8
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Ablynx NV

Eligibility Criteria

Inclusion Criteria

  • •1\. Completed the Final (28 day) FU visit in Study ALX0681\-C301\.
  • •2\. Is \>\= 18 years of age at the time of signing the informed consent form (ICF).
  • •3\. Provided informed consent prior to initiation of any study specific activity/procedure.

Exclusion Criteria

  • •1\. Not being able/willing to comply with the study protocol procedures.
  • •2\. Currently enrolled in a clinical study with another investigational drug or device.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-001503-23-ATAblynx NV104
Active, not recruiting
Phase 1
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)
EUCTR2016-001503-23-GBAblynx NV104
Active, not recruiting
Phase 1
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-001503-23-CZAblynx NV104
Active, not recruiting
Phase 1
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-001503-23-NLAblynx NV92
Active, not recruiting
Phase 1
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)
EUCTR2016-001503-23-FRAblynx NV92